Company financial health
Search documents
AvePoint (AVPT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
ZACKS· 2026-02-27 01:31
Core Insights - AvePoint, Inc. reported a revenue of $114.69 million for the quarter ended December 2025, reflecting a year-over-year increase of 28.6% [1] - The earnings per share (EPS) for the quarter was $0.10, a significant improvement from -$0.04 in the same quarter last year [1] - The reported revenue exceeded the Zacks Consensus Estimate of $111.11 million by 3.22%, while the EPS surpassed the consensus estimate of $0.09 by 11.11% [1] Financial Metrics - Annual recurring revenue (ARR) reached $416.8 million, slightly above the average estimate of $415.8 million from two analysts [4] - Revenue from maintenance services was reported at $0.98 million, exceeding the average estimate of $0.77 million [4] - Revenue from services amounted to $14.65 million, significantly higher than the two-analyst average estimate of $12.28 million [4] Stock Performance - AvePoint's shares have declined by 17.5% over the past month, contrasting with a 0.6% increase in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]
Compared to Estimates, Cava (CAVA) Q4 Earnings: A Look at Key Metrics
ZACKS· 2026-02-25 02:01
Cava Group (CAVA) reported $274.99 million in revenue for the quarter ended December 2025, representing a year-over-year increase of 20.9%. EPS of $0.04 for the same period compares to $0.05 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $268.17 million, representing a surprise of +2.54%. The company delivered an EPS surprise of +55.64%, with the consensus EPS estimate being $0.03.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wa ...
Here's What Key Metrics Tell Us About Halozyme Therapeutics (HALO) Q4 Earnings
ZACKS· 2026-02-18 00:30
Core Insights - Halozyme Therapeutics reported a revenue of $451.77 million for the quarter ended December 2025, marking a 51.6% increase year-over-year, while EPS was -$0.24 compared to $1.26 in the same quarter last year [1] - The revenue exceeded the Zacks Consensus Estimate of $448.62 million by 0.7%, but the EPS fell short of the consensus estimate of $2.15 by 111.16% [1] Revenue Breakdown - Product sales, net reached $122.67 million, surpassing the average estimate of $115.69 million by analysts, reflecting a year-over-year increase of 54.6% [4] - Royalties amounted to $257.97 million, slightly below the estimated $262.14 million, but still showing a 51.4% increase compared to the previous year [4] - Revenues from collaboration agreements were reported at $71.13 million, exceeding the average estimate of $61.31 million, representing a 47.5% year-over-year growth [4] Stock Performance - Over the past month, shares of Halozyme Therapeutics have returned +11.6%, contrasting with a -1.4% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]
Here's What Key Metrics Tell Us About American International Group (AIG) Q4 Earnings
ZACKS· 2026-02-11 00:31
Core Insights - American International Group (AIG) reported $6.95 billion in revenue for Q4 2025, a year-over-year increase of 1.4% [1] - The earnings per share (EPS) for the same period was $1.96, compared to $1.30 a year ago, exceeding the consensus estimate of $1.89 by 3.54% [1] - The revenue fell short of the Zacks Consensus Estimate of $7.1 billion, resulting in a surprise of -2.22% [1] Financial Performance Metrics - General Insurance - North America Commercial reported a loss ratio of 59.7%, better than the estimated 65.7% [4] - General Insurance - International Commercial had a combined ratio of 88.8%, slightly worse than the estimated 86.4% [4] - General Insurance - North America Commercial's combined ratio was 84.7%, outperforming the estimated 88.5% [4] - General Insurance - International Commercial's expense ratio was 31.7%, higher than the estimated 30.6% [4] - Total net investment income was $872 million, significantly below the estimated $1 billion, reflecting a year-over-year decline of 33.6% [4] - General Insurance - North America Commercial net premiums earned were $2.17 billion, slightly below the estimated $2.19 billion [4] - General Insurance - International Commercial net premiums earned were $2.22 billion, exceeding the estimated $2.15 billion [4] - General Insurance - Global Personal net premiums earned were $1.6 billion, in line with the estimated $1.59 billion [4] - General Insurance net investment income was $881 million, close to the average estimate of $881.82 million, showing a year-over-year increase of 13.1% [4] - General Insurance net premiums earned totaled $5.99 billion, slightly above the estimated $5.93 billion, representing a year-over-year change of 0.3% [4] Stock Performance - AIG shares returned +1.1% over the past month, while the Zacks S&P 500 composite remained unchanged [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market [3]
Amentum (AMTM) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
ZACKS· 2026-02-10 01:01
Core Insights - Amentum Holdings reported a revenue of $3.24 billion for the quarter ended December 2025, reflecting a 5.2% decline year-over-year and a revenue surprise of -2.98% compared to the Zacks Consensus Estimate of $3.34 billion. The EPS was $0.54, slightly up from $0.51 in the previous year, with an EPS surprise of +1.89% against the consensus estimate of $0.53 [1]. Financial Performance - Revenue from Global Engineering Solutions (GES) was $1.9 billion, falling short of the average estimate of $2.04 billion from three analysts [4]. - Revenue from Digital Solutions (DS) reached $1.34 billion, exceeding the average estimate of $1.27 billion from three analysts [4]. - Adjusted EBITDA for GES was reported at $160 million, slightly above the average estimate of $157.08 million from two analysts [4]. - Adjusted EBITDA for DS was $103 million, surpassing the average estimate of $99.45 million from two analysts [4]. Stock Performance - Amentum's shares have returned +11.6% over the past month, contrasting with a -0.2% change in the Zacks S&P 500 composite [3]. - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3].
Here's What Key Metrics Tell Us About Amazon (AMZN) Q4 Earnings
ZACKS· 2026-02-06 00:02
Core Insights - Amazon reported revenue of $213.39 billion for the quarter ended December 2025, reflecting a year-over-year increase of 13.6% and a surprise of +0.91% over the Zacks Consensus Estimate of $211.46 billion [1] - The earnings per share (EPS) for the quarter was $1.95, slightly below the consensus estimate of $1.98, resulting in an EPS surprise of -1.52% [1] Revenue Performance - Subscription services saw a year-over-year change of +12%, exceeding the average estimate of +10.8% [4] - Physical stores reported a +5% change compared to the estimated +4.8% [4] - Amazon Web Services (AWS) net sales grew by +24%, surpassing the average estimate of +21.8% [4] - Third-party seller services experienced a +10% change, close to the average estimate of +10.7% [4] Net Sales Breakdown - AWS net sales reached $35.58 billion, exceeding the estimated $35.03 billion, representing a +23.6% change year-over-year [4] - Physical stores generated $5.86 billion in net sales, slightly below the estimated $5.88 billion, with a +5% year-over-year change [4] - Online stores reported net sales of $82.99 billion, above the estimated $82.4 billion, marking a +9.8% change [4] - Subscription services net sales were $13.12 billion, exceeding the average estimate of $12.86 billion, reflecting a +14% year-over-year change [4] - North America net sales totaled $127.08 billion, slightly below the estimate of $127.14 billion, with a +10% year-over-year change [4] - Advertising services net sales reached $21.32 billion, surpassing the estimated $21.21 billion, representing a +23.3% change [4] - International net sales were $50.72 billion, exceeding the estimated $49.34 billion, with a +16.8% year-over-year change [4] - Third-party seller services net sales were $52.82 billion, above the average estimate of $52.27 billion, reflecting a +11.2% year-over-year change [4] Stock Performance - Amazon's shares have returned -3.6% over the past month, while the Zacks S&P 500 composite has increased by +0.5% [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]
Here's What Key Metrics Tell Us About MasterCraft Boat Holdings, Inc. (MCFT) Q2 Earnings
ZACKS· 2026-02-05 16:01
Core Insights - MasterCraft Boat Holdings, Inc. reported revenue of $71.76 million for the quarter ended December 2025, marking a year-over-year increase of 13.2% and exceeding the Zacks Consensus Estimate of $69.87 million by 2.71% [1] - The company achieved an EPS of $0.29, significantly higher than the $0.10 reported a year ago, resulting in an EPS surprise of 77.59% compared to the consensus estimate of $0.16 [1] Financial Performance Metrics - MasterCraft's unit sales volume reached 409, slightly above the average estimate of 408, while the consolidated unit sales volume was 583, exceeding the average estimate of 563 [4] - The net sales per unit for MasterCraft was reported at $151.00, matching the average estimate, while the consolidated net sales per unit was $123.00, slightly below the average estimate of $125.05 [4] - Net sales for MasterCraft amounted to $61.74 million, surpassing the average estimate of $61.55 million, reflecting a year-over-year change of 12.1%, while net sales for Pontoon reached $10.02 million, exceeding the average estimate of $8.75 million with a year-over-year increase of 21.2% [4] Stock Performance - Over the past month, shares of MasterCraft Boat Holdings, Inc. have returned 12.2%, significantly outperforming the Zacks S&P 500 composite, which saw a change of 0.5% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]
Rexford Industrial (REXR) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
ZACKS· 2026-02-05 01:31
Financial Performance - For the quarter ended December 2025, Rexford Industrial reported revenue of $248.1 million, reflecting a year-over-year increase of 2.1% [1] - Earnings per share (EPS) for the quarter was $0.59, a significant increase from $0.27 in the same quarter last year [1] - The reported revenue was slightly below the Zacks Consensus Estimate of $250.22 million, resulting in a revenue surprise of -0.85% [1] - The company achieved an EPS surprise of +1.01%, with the consensus EPS estimate being $0.58 [1] Key Metrics - Rental income was reported at $243.23 million, compared to the average estimate of $247.13 million, representing a year-over-year change of +1.5% [4] - Management and leasing services revenue was $0.2 million, exceeding the average estimate of $0.12 million, with a year-over-year increase of +18% [4] - Interest income was reported at $4.67 million, below the average estimate of $6.07 million, but showed a substantial year-over-year increase of +56.1% [4] - Net earnings per share (diluted) was reported at -$0.30, compared to the average estimate of $0.26 [4] Stock Performance - Shares of Rexford Industrial have returned +4.5% over the past month, outperforming the Zacks S&P 500 composite's +0.9% change [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]
Here's What Key Metrics Tell Us About Essex Property Trust (ESS) Q4 Earnings
ZACKS· 2026-02-05 01:00
Core Insights - Essex Property Trust reported revenue of $479.63 million for the quarter ended December 2025, reflecting a year-over-year increase of 5.5% [1] - The company's EPS was $3.98, slightly down from $4.00 in the same quarter last year, indicating a -0.52% surprise compared to the consensus estimate of $4.00 [1] - The revenue exceeded the Zacks Consensus Estimate of $476.57 million by 0.64% [1] Financial Performance Metrics - Financial occupancy for the same-property portfolio was reported at 96.3%, surpassing the average estimate of 96% from four analysts [4] - Total revenues from rental and other property reached $477.32 million, exceeding the seven-analyst average estimate of $475.08 million, with a year-over-year change of +5.6% [4] - Management and other fees from affiliates generated $2.3 million, slightly above the average estimate of $2.29 million, but down -4.7% year-over-year [4] - Same-property revenues totaled $414.85 million, marginally above the three-analyst average estimate of $414.75 million, reflecting a +0.9% year-over-year change [4] - Rental income was reported at $470.11 million, slightly above the estimate of $469.95 million, with a +5.6% change compared to the previous year [4] - Net earnings per share (diluted) were $1.25, below the five-analyst average estimate of $1.38 [4] Stock Performance - Over the past month, shares of Essex Property Trust have returned -3.5%, contrasting with the Zacks S&P 500 composite's +0.9% change [3] - The stock currently holds a Zacks Rank 4 (Sell), suggesting potential underperformance relative to the broader market in the near term [3]
McKesson (MCK) Reports Q3 Earnings: What Key Metrics Have to Say
ZACKS· 2026-02-05 00:01
Core Insights - McKesson reported revenue of $106.16 billion for the quarter ended December 2025, reflecting an 11.4% increase year-over-year and surpassing the Zacks Consensus Estimate of $105.66 billion by 0.47% [1] - The company's EPS for the quarter was $9.34, up from $8.03 in the same quarter last year, also exceeding the consensus EPS estimate of $9.31 by 0.35% [1] Revenue Performance - Medical-Surgical Solutions revenue was $2.99 billion, slightly below the average estimate of $3.05 billion, with a year-over-year increase of 1.4% [4] - Prescription Technology Solutions revenue matched the average estimate at $1.5 billion, showing a year-over-year growth of 9.4% [4] - Other revenue reached $335 million, exceeding the estimated $297.61 million [4] - North American Pharmaceutical revenue was $88.32 billion, slightly below the average estimate of $88.6 billion, with a year-over-year increase of 1.4% [4] - Oncology & Multispecialty revenue was $13.01 billion, surpassing the average estimate of $12.48 billion [4] Adjusted Operating Profit - Adjusted Operating Profit for Medical-Surgical Solutions was $265 million, below the estimate of $278.29 million [4] - Adjusted Operating Profit for Prescription Technology Solutions was $277 million, exceeding the average estimate of $264.4 million [4] - Adjusted Operating Profit for Oncology & Multispecialty was $366 million, above the average estimate of $353.98 million [4] - Adjusted Operating Profit for Corporate was -$156 million, better than the estimate of -$180.91 million [4] - Adjusted Operating Profit for North American Pharmaceutical was $872 million, exceeding the average estimate of $855.24 million [4] - Adjusted Operating Profit for Other was $28 million, surpassing the average estimate of $14.6 million [4] Stock Performance - McKesson's shares have returned 3% over the past month, outperforming the Zacks S&P 500 composite's return of 0.9% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]